{
  "url": "https://finance.yahoo.com/news/luzerner-kantonalbank-reports-second-quarter-043542369.html",
  "authorsByline": "Simply Wall St",
  "articleId": "6c5816a5a7474b3baa8fe8ae9504ac29",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-25T04:35:42+00:00",
  "addDate": "2025-08-25T05:20:31.629699+00:00",
  "refreshDate": "2025-08-25T05:20:31.629700+00:00",
  "score": 1.0,
  "title": "Luzerner Kantonalbank Reports Second Quarter 2025 Earnings",
  "description": "Luzerner Kantonalbank ( VTX:LUKN ) Second Quarter 2025 Results Key Financial Results Revenue: CHF166.1m (up 6.8% from...",
  "content": "AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\n\nLooking ahead, revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Banks industry in Switzerland.\n\nThe company's shares are up 2.5% from a week ago.\n\nWhile it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Luzerner Kantonalbank's balance sheet.\n\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n\n\n\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/markets/ch/financials/banks?blueprint=4014143&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
    "https://simplywall.st/company/id/38983043-FEA3-4690-A667-05D9C6842173/past?blueprint=4014143&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/company/id/38983043-FEA3-4690-A667-05D9C6842173/health?blueprint=4014143&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/LUKN.SW",
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4014143&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare"
  ],
  "labels": [],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Simply Wall St",
      "weight": 0.08288634
    },
    {
      "name": "Luzerner Kantonalbank",
      "weight": 0.07540896
    },
    {
      "name": "analyst forecasts",
      "weight": 0.07382599
    },
    {
      "name": "historical data",
      "weight": 0.07048466
    },
    {
      "name": "fundamental data",
      "weight": 0.06587307
    },
    {
      "name": "early diagnostics",
      "weight": 0.063602105
    },
    {
      "name": "financial advice",
      "weight": 0.062027633
    },
    {
      "name": "long-term focused analysis",
      "weight": 0.055881437
    },
    {
      "name": "drug discovery",
      "weight": 0.055372957
    },
    {
      "name": "Luzerner Kantonalbanks balance sheet",
      "weight": 0.053990226
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.9853515625
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.9697265625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.94970703125
    }
  ],
  "sentiment": {
    "positive": 0.660983,
    "negative": 0.030051352,
    "neutral": 0.30896565
  },
  "summary": "The company's shares have risen by 2.5% since the second quarter of 2018. Looking ahead, Luzerner Kantonalbank is predicted to grow by 1.5%, compared to the 2.0% growth forecast for the Banks industry in Switzerland. This article discusses how to learn more about a company's balance sheet and its future prospects.",
  "shortSummary": "The future of healthcare is shifting focus to 20 promising new entrants, including Luzerner Kantonalbank, who are all $10bn in market value.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": true,
  "reprintGroupId": "93c064fca9b143f5ad438755866da827",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4014143&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nRakovina Therapeutics\nMarket Cap: US$10.8m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.37\n7D\n-9.8%\n1Y\nn/a\nCosmo Pharmaceuticals\nMarket Cap: US$924.5m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\nn/a\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$20.5m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$3.25\n7D\n12.8%\n1Y\n-79.3%\nImmunoPrecise Antibodies\nMarket Cap: US$147.7m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$3.20\n7D\n60.0%\n1Y\n295.1%\nGeneDx Holdings\nMarket Cap: US$3.7b\nA genomics company, provides genetic testing services.\nWGS\nUS$128.67\n7D\n2.2%\n1Y\n261.5%\nEvolent Health\nMarket Cap: US$1.1b\nThrough its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.\nEVH\nUS$9.60\n7D\n6.4%\n1Y\n-69.6%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.56\n7D\n-1.4%\n1Y\n3.1%\nSpectral AI\nMarket Cap: US$55.9m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$2.09\n7D\n-1.4%\n1Y\n43.2%\nRevenio Group Oyj\nMarket Cap: US$657.1m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.4b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$70.10\n7D\n5.7%\n1Y\n7.6%\nCareCloud\nMarket Cap: US$119.8m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$2.83\n7D\n4.0%\n1Y\n-0.7%\nSimulations Plus\nMarket Cap: US$293.3m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.57\n7D\n0.8%\n1Y\n-60.7%\nNano-X Imaging\nMarket Cap: US$259.6m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$4.06\n7D\n-8.1%\n1Y\n-42.3%\nPerimeter Medical Imaging AI\nMarket Cap: US$26.2m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.17\n7D\n-1.4%\n1Y\n-39.1%\nCeriBell\nMarket Cap: US$442.2m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$12.06\n7D\n-2.0%\n1Y\nn/a\nHeartSciences\nMarket Cap: US$13.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.65\n7D\n8.0%\n1Y\n-1.9%\nGuardant Health\nMarket Cap: US$7.7b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$61.40\n7D\n3.2%\n1Y\n129.6%\nOmniAb\nMarket Cap: US$227.0m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.85\n7D\n-8.0%\n1Y\n-57.8%\nBioXcel Therapeutics\nMarket Cap: US$72.5m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$4.98\n7D\n-9.1%\n1Y\n-54.2%\nXtalPi Holdings\nMarket Cap: US$40.9b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.20\n7D\n14.3%\n1Y\nn/a\nNeuroOne Medical Technologies\nMarket Cap: US$39.2m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.78\n7D\n-5.5%\n1Y\n-3.8%\nLantheus Holdings\nMarket Cap: US$4.0b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$58.21\n7D\n4.0%\n1Y\n-45.8%\nAbsci\nMarket Cap: US$483.3m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.63\n7D\n-10.2%\n1Y\n-41.4%\nHealwell AI\nMarket Cap: US$383.8m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.99\n7D\n4.2%\n1Y\n-34.9%\nPersonalis\nMarket Cap: US$428.3m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.83\n7D\n-0.4%\n1Y\n-16.7%\nVeradigm\nMarket Cap: US$823.7m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.85\n7D\n4.3%\n1Y\n-49.7%"
    },
    {
      "url": "https://simplywall.st/markets/ch/financials/banks?blueprint=4014143&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
      "text": "The Banks industry is up 1.4% in the last week, with Banque Cantonale Vaudoise up 3.5%. This takes the industry's 12 month performance to a gain of 11%. Earnings are forecast to grow by 2.5% annually.\nHas the Swiss Banks Industry valuation changed over the past few years?\n| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |\n|---|---|---|---|---|---|---|\n| Mon, 25 Aug 2025 | CHF 41.9b | CHF 7.6b | CHF 2.7b | 15.3x | 15.4x | 5.5x |\n| Wed, 23 Jul 2025 | CHF 41.8b | CHF 7.6b | CHF 2.7b | 14.2x | 15.2x | 5.5x |\n| Fri, 20 Jun 2025 | CHF 40.0b | CHF 7.6b | CHF 2.7b | 13.6x | 14.8x | 5.3x |\n| Sun, 18 May 2025 | CHF 40.6b | CHF 7.6b | CHF 2.7b | 13.8x | 15x | 5.4x |\n| Tue, 15 Apr 2025 | CHF 40.1b | CHF 7.6b | CHF 2.7b | 13.6x | 14.8x | 5.3x |\n| Thu, 13 Mar 2025 | CHF 40.3b | CHF 7.5b | CHF 2.7b | 13.6x | 15.2x | 5.4x |\n| Sat, 08 Feb 2025 | CHF 39.6b | CHF 7.5b | CHF 2.7b | 13.3x | 14.7x | 5.3x |\n| Mon, 06 Jan 2025 | CHF 37.7b | CHF 7.5b | CHF 2.7b | 12.8x | 14x | 5x |\n| Wed, 04 Dec 2024 | CHF 37.3b | CHF 7.5b | CHF 2.7b | 12.6x | 13.8x | 5x |\n| Fri, 01 Nov 2024 | CHF 37.3b | CHF 7.5b | CHF 2.7b | 12.7x | 13.9x | 5x |\n| Sun, 29 Sep 2024 | CHF 37.2b | CHF 7.5b | CHF 2.7b | 12.7x | 13.9x | 5x |\n| Tue, 27 Aug 2024 | CHF 37.8b | CHF 7.5b | CHF 2.7b | 12.8x | 14.1x | 5.1x |\n| Thu, 25 Jul 2024 | CHF 38.2b | CHF 7.5b | CHF 2.7b | 12.8x | 14.2x | 5.1x |\n| Sat, 22 Jun 2024 | CHF 38.5b | CHF 7.5b | CHF 2.7b | 13x | 14.3x | 5.1x |\n| Mon, 20 May 2024 | CHF 39.2b | CHF 7.5b | CHF 2.7b | 13.3x | 14.5x | 5.2x |\n| Wed, 17 Apr 2024 | CHF 40.0b | CHF 7.5b | CHF 2.7b | 13.6x | 14.9x | 5.4x |\n| Fri, 15 Mar 2024 | CHF 39.7b | CHF 7.3b | CHF 2.6b | 14.4x | 15.1x | 5.4x |\n| Sun, 11 Feb 2024 | CHF 39.3b | CHF 7.2b | CHF 2.6b | 14.4x | 15.3x | 5.5x |\n| Tue, 09 Jan 2024 | CHF 39.6b | CHF 7.2b | CHF 2.5b | 14.1x | 15.6x | 5.5x |\n| Thu, 07 Dec 2023 | CHF 38.6b | CHF 7.2b | CHF 2.5b | 14.1x | 15.2x | 5.3x |\n| Sat, 04 Nov 2023 | CHF 38.8b | CHF 7.2b | CHF 2.5b | 14.6x | 15.3x | 5.4x |\n| Mon, 02 Oct 2023 | CHF 38.7b | CHF 7.1b | CHF 2.5b | 15.2x | 15.5x | 5.4x |\n| Wed, 30 Aug 2023 | CHF 38.4b | CHF 7.1b | CHF 2.5b | 15.4x | 15.6x | 5.5x |\n| Fri, 28 Jul 2023 | CHF 38.4b | CHF 6.7b | CHF 2.4b | 15.4x | 16.3x | 5.7x |\n| Sun, 25 Jun 2023 | CHF 37.4b | CHF 6.7b | CHF 2.3b | 15.7x | 16x | 5.6x |\n| Tue, 23 May 2023 | CHF 37.5b | CHF 6.7b | CHF 2.3b | 16x | 16x | 5.6x |\n| Thu, 20 Apr 2023 | CHF 38.2b | CHF 6.7b | CHF 2.3b | 16.1x | 16.4x | 5.7x |\n| Sat, 18 Mar 2023 | CHF 36.5b | CHF 6.5b | CHF 2.3b | 15.8x | 16.2x | 5.6x |\n| Mon, 13 Feb 2023 | CHF 37.0b | CHF 6.5b | CHF 2.2b | 16.1x | 16.6x | 5.7x |\n| Wed, 11 Jan 2023 | CHF 36.5b | CHF 6.5b | CHF 2.2b | 15.8x | 16.5x | 5.6x |\n| Fri, 09 Dec 2022 | CHF 36.3b | CHF 6.5b | CHF 2.2b | 15.9x | 16.4x | 5.6x |\n| Sun, 06 Nov 2022 | CHF 36.3b | CHF 6.5b | CHF 2.2b | 15.7x | 16.4x | 5.6x |\n| Tue, 04 Oct 2022 | CHF 36.3b | CHF 6.5b | CHF 2.2b | 15.3x | 16.4x | 5.6x |\n| Thu, 01 Sep 2022 | CHF 36.5b | CHF 6.5b | CHF 2.2b | 15.9x | 16.5x | 5.6x |\n16.5x\nWhich industries have driven the changes within the Swiss Financials industry?\n| CH Market | 1.55% | |\n| Financials | 0.95% | |\n| Banks | 1.27% | |\n| Regional Banks | 1.28% | |\n| Diversified Banks | 1.06% |\nWhich companies have driven the market over the last 7 days?\n| Company | Last Price | 7D | 1Y | Valuation | |\n|---|---|---|---|---|---|\n| BCVN Banque Cantonale Vaudoise | CHF 95.80 | 3.5% +CHF 279.2m | 4.1% | PB2.2x | |\n| LUKN Luzerner Kantonalbank | CHF 76.50 | 2.5% +CHF 93.7m | 16.3% | PB0.9x | |\n| SGKN St. Galler Kantonalbank | CHF 510.00 | 1.6% +CHF 47.8m | 21.1% | PB1x | |\n| LLBN Liechtensteinische Landesbank | CHF 86.00 | 1.1% +CHF 23.6m | 14.4% | PB1.2x | |\n| ZUGER Zuger Kantonalbank | CHF 8.78k | 0.9% +CHF 23.0m | 5.8% | PB1.6x |"
    },
    {
      "url": "https://simplywall.st/company/id/38983043-FEA3-4690-A667-05D9C6842173/health?blueprint=4014143&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Luzerner Kantonalbank Balance Sheet Health\nFinancial Health criteria checks 5/6\nLuzerner Kantonalbank has total assets of CHF59.7B and total equity of CHF4.1B. Total deposits are CHF29.0B, and total loans are CHF44.1B.\nKey information\n14.6x\nAsset to equity ratio\nn/a\nNet interest margin\n| Total deposits | CHF 29.03b |\n| Loan to deposit ratio | High |\n| Bad loans | 0.1% |\n| Allowance for bad loans | Sufficient |\n| Current ratio | Low |\n| Cash & equivalents | CHF 9.60b |\nRecent financial health updates\nNo updates\nFinancial Position Analysis\nDebt to Equity History and Analysis\nBalance Sheet\nFinancial Institutions Analysis\nAsset Level: LUKN's Assets to Equity ratio (14.6x) is moderate.\nAllowance for Bad Loans: LUKN has a sufficient allowance for bad loans (336%).\nLow Risk Liabilities: 52% of LUKN's liabilities are made up of primarily low risk sources of funding.\nLoan Level: LUKN has an appropriate level of Loans to Assets ratio (74%).\nLow Risk Deposits: LUKN's Loans to Deposits ratio (152%) is high.\nLevel of Bad Loans: LUKN has an appropriate level of bad loans (0.1%).\nDiscover healthy companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:09 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nLuzerner Kantonalbank AG is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Tobias Brutsch | Bank Vontobel AG |\n| Yannik Ryf | Z\u00fcrcher Kantonalbank |\n| Ausano Cajrati Crivelli Mesmer Nobili | Z\u00fcrcher Kantonalbank |"
    },
    {
      "url": "https://simplywall.st/company/id/38983043-FEA3-4690-A667-05D9C6842173/past?blueprint=4014143&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Luzerner Kantonalbank Past Earnings Performance\nPast criteria checks 3/6\nLuzerner Kantonalbank has been growing earnings at an average annual rate of 7.7%, while the Banks industry saw earnings growing at 6.6% annually. Revenues have been growing at an average rate of 4.7% per year. Luzerner Kantonalbank's return on equity is 7.2%, and it has net margins of 43.2%.\nKey information\n7.70%\nEarnings growth rate\n3.43%\nEPS growth rate\n| Banks Industry Growth | 3.07% |\n| Revenue growth rate | 4.74% |\n| Return on equity | 7.17% |\n| Net Margin | 43.19% |\n| Last Earnings Update | 30 Jun 2025 |\nRecent past performance updates\nRevenue & Expenses Breakdown\nHow Luzerner Kantonalbank makes and spends money. Based on latest reported earnings, on an LTM basis.\nEarnings and Revenue History\n| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |\n|---|---|---|---|---|\n| 30 Jun 25 | 678 | 293 | 337 | 0 |\n| 31 Mar 25 | 667 | 288 | 331 | 0 |\n| 31 Dec 24 | 651 | 287 | 325 | 0 |\n| 30 Sep 24 | 644 | 283 | 324 | 0 |\n| 30 Jun 24 | 630 | 282 | 317 | 0 |\n| 31 Mar 24 | 623 | 279 | 313 | 0 |\n| 31 Dec 23 | 615 | 265 | 308 | 0 |\n| 30 Sep 23 | 614 | 257 | 302 | 0 |\n| 30 Jun 23 | 587 | 244 | 280 | 0 |\n| 31 Mar 23 | 589 | 232 | 293 | 0 |\n| 31 Dec 22 | 586 | 227 | 292 | 0 |\n| 30 Sep 22 | 580 | 222 | 294 | 0 |\n| 30 Jun 22 | 586 | 221 | 291 | 0 |\n| 31 Mar 22 | 581 | 222 | 289 | 0 |\n| 31 Dec 21 | 581 | 221 | 287 | 0 |\n| 30 Sep 21 | 575 | 220 | 283 | 0 |\n| 30 Jun 21 | 571 | 218 | 290 | 0 |\n| 31 Mar 21 | 558 | 219 | 274 | 0 |\n| 31 Dec 20 | 531 | 211 | 269 | 0 |\n| 30 Sep 20 | 515 | 212 | 261 | 0 |\n| 30 Jun 20 | 512 | 208 | 259 | 0 |\n| 31 Mar 20 | 492 | 201 | 247 | 0 |\n| 31 Dec 19 | 504 | 205 | 253 | 0 |\n| 30 Sep 19 | 499 | 205 | 251 | 0 |\n| 30 Jun 19 | 487 | 201 | 248 | 0 |\n| 31 Mar 19 | 484 | 201 | 246 | 0 |\n| 31 Dec 18 | 482 | 200 | 245 | 0 |\n| 30 Sep 18 | 475 | 197 | 243 | 0 |\n| 30 Jun 18 | 481 | 202 | 243 | 0 |\n| 31 Mar 18 | 481 | 202 | 242 | 0 |\n| 31 Dec 17 | 475 | 198 | 239 | 0 |\n| 30 Sep 17 | 477 | 199 | 238 | 0 |\n| 30 Jun 17 | 459 | 194 | 225 | 0 |\n| 31 Mar 17 | 455 | 191 | 232 | 0 |\n| 31 Dec 16 | 447 | 187 | 227 | 0 |\n| 30 Sep 16 | 438 | 183 | 222 | 0 |\n| 30 Jun 16 | 436 | 178 | 226 | 0 |\n| 31 Mar 16 | 426 | 177 | 216 | 0 |\n| 31 Dec 15 | 429 | 180 | 216 | 0 |\n| 30 Sep 15 | 421 | 177 | 214 | 0 |\n| 30 Jun 15 | 423 | 179 | 206 | 0 |\n| 31 Mar 15 | 433 | 181 | 215 | 0 |\n| 31 Dec 14 | 440 | 182 | 215 | 0 |\n| 30 Sep 14 | 432 | 179 | 217 | 0 |\nQuality Earnings: LUKN has high quality earnings.\nGrowing Profit Margin: LUKN's current net profit margins (43.2%) are lower than last year (44.8%).\nFree Cash Flow vs Earnings Analysis\nPast Earnings Growth Analysis\nEarnings Trend: LUKN's earnings have grown by 7.7% per year over the past 5 years.\nAccelerating Growth: LUKN's earnings growth over the past year (3.7%) is below its 5-year average (7.7% per year).\nEarnings vs Industry: LUKN earnings growth over the past year (3.7%) exceeded the Banks industry -0.3%.\nReturn on Equity\nHigh ROE: LUKN's Return on Equity (7.2%) is considered low.\nReturn on Assets\nReturn on Capital Employed\nDiscover strong past performing companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/25 04:09 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nLuzerner Kantonalbank AG is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Tobias Brutsch | Bank Vontobel AG |\n| Yannik Ryf | Z\u00fcrcher Kantonalbank |\n| Ausano Cajrati Crivelli Mesmer Nobili | Z\u00fcrcher Kantonalbank |"
    }
  ],
  "argos_summary": "The article highlights how artificial intelligence is poised to transform healthcare, improving diagnostics, personalized medicine, operational efficiency, remote care, and drug discovery. It lists 20 AI\u2011driven companies\u2014most under $10\u202fbillion in market cap\u2014that are developing solutions from early disease detection to AI\u2011powered therapeutics. Revenue for these firms is projected to grow modestly at 1.5% annually over the next three years, slightly below the Swiss banks\u2019 2.0% growth forecast. The piece also briefly compares the Swiss banking sector\u2019s performance, noting stable earnings growth and a modest rise in market cap, but the focus remains on the AI healthcare opportunity.",
  "argos_id": "DMRZ89EAX"
}